Clinical trial · Interventional
Panitumumab, Cisplatin, and Pelvic Radiation Therapy in Treating Patients With Stage IB, Stage II, or Stage III Cervical Cancer
A Two-Stage Multicenter Phase II Trial of Concurrent Panitumumab Immunotherapy, Cisplatin Chemotherapy and Pelvic Radiotherapy for Primary Cancer of the Uterine Cervix Stage IB-IIIB
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving panitumumab and cisplatin together with pelvic radiation therapy may be effective in treating patients with cervical cancer. PURPOSE: This phase II trial is studying the side effects of giving panitumumab and cisplatin together with pelvic radiation therapy in treating patients with stage IB, stage II, or stage III cervical cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Cancer | Malignant Cervical Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| brachytherapy | Radiation | — | UNRESOLVED |
| cisplatin | Drug | Cisplatin | ALIAS |
| external beam radiation therapy | Radiation | — | UNRESOLVED |
| panitumumab | Biological | Panitumumab | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Progression-free survival at 4 months by MRI according to RECIST criteria
- measure
- Rate of skin and/or gastrointestinal toxicity CTCAE grade 4 at 4 months
Secondary outcomes (6)
- measure
- Overall response rate at 4 months according to RECIST criteria
- measure
- Progression-free survival at 12 and 24 months according to RECIST criteria
- measure
- Overall survival at 12 and 24 months
- measure
- Rate of severe adverse events according to CTCAE at 4 months
- measure
- Rate of post-treatment severe adverse events according to CTCAE at 12 and 24 months
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed cervical cancer, including the following subtypes: * Squamous small-cell or large-cell carcinoma * Adenosquamous cell carcinoma * Adenocarcinoma * Keratinizing or non-keratinizing carcinoma * Stage IB-IIIB disease * No para-aortic lymph node metastases or clinical indication for para-aortic field irradiation * No predominant and clinically effective neuroendocrine tumor cell differentiation PATIENT CHARACTERISTICS: * WH0 performance status 0-2 * Serum creatinine clearance \> 50 mL/min * No other prior or current malignancy within the past 5 years except adequately treated nonmelanoma skin cancer or carcinoma in-situ of the cervix * No acute life-threatening vaginal hemorrhage (requiring emergency irradiation or RBC transfusion) PRIOR CONCURRENT THERAPY: * Not specified
References
Publications (0)
Data not yet available